Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Top Authors for All Days ending 2016-12-01: GROWTH Trends @Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

Curator: Aviva Lev-Ari, PhD, RN

 

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

12/1/2016

1,107,643

4,972

3,398

2,279

Be proud to be part of this team !!!

Forthcoming SEVEN e-Books in 2016 AND Eight e-Books on Amazon.com

https://pharmaceuticalintelligence.com/2016/04/24/new-e-book-titles-forthcoming-on-amazon-com-in-2016-from-lpbi-groups-biomed-e-series-forthcoming-cover-pages/

WE ARE ON AMAZON.COM

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

 

GROWTH TRENDS: e-Readers, # of articles, NIH Clicks, Nature Clicks

2013, 2014, 2015, 2016

Scientific Journal Site Statistics

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

07/29/2013   217,356 1,138 1,389 705

12/01/2013   287,645 1,428 1,676 828

02/09/2014   325,039 1,665 1,793 892

03/05/2014   338,958 1,717 1,830 965

03/21/2014   347,667 1,750 1,838 974

03/31/2014  352,683 1,768 1,869 991

05/12/2014  373.696  1,878  1,944  1,035

06/18/2014  393,111  1,992  1,982  1,087

7/27/2014  418,570  2,098  2.050  1,124

9/2/2014  444,222  2,226  2,104  1,170

10/9/2014 471,117  2,337  2,147  1,216

11/4/2014  492,736  2,471  2,194 1,234

2/15/2015  572,027 2,727  2,358  1,345

3/10/2015 591,520 2,808 2,373 1,369

6/7/2015   661,215 3,007 2,562 1,535

7/27/2015 694,298 3,085 2,583 1,572

8/18/2015 709,609  3,173 2,613 1,573

02/18/2016  886,454  4,162   2,911  1,813 

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

12/1/2016

1,107,643

4,972

3,398

2,279

 

Be proud to be part of this team !!!

 

Top Authors for all days ending 2016-12-01 (Summarized)

• All time

	Top Posts for all days ending 2016-12-03 (Summarized)
	All Time
Title		Views
Home page / Archives		402,487
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? – Dr. Larry Bernstein		14,861
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) Aviva Lev-Ari, et al		9,080
Recent comprehensive review on the role of ultrasound in breast cancer management Dr. Dror Nir		6,720
Paclitaxel vs Abraxane (albumin-bound paclitaxel) Tilda Barliya, PhD		5,695
Our TEAM	Aviva Lev-Ari, PhD, RN	5,539
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) Tilda Barliya, PhD		5,051
Akt inhibition for cancer treatment, where do we stand today? Ziv Raviv, PhD		3,843
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses – Zohi Sternberg, PhD		3,740
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care – Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN		3,418
Volume One: Perspectives on Nitric Oxide in Disease Mechanisms Editors: Dr. Larry Bernstein, Aviral Vatsa, PhD and Stephen J Williams, PhD		3,389
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad – Demet Sag, PhD		3,181
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo – Stephen J Williams, PhD		3,149
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications – Aviva Lev-Ari, PhD, RN		3,082
Founder	Aviva Lev-Ari, PhD, RN	3,075
BioMed e-Series – Aviva Lev-Ari, PhD, RN		2,944
The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) Aviva Lev-Ari, PhD, RN et al		2,728
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology – Tilda Barliya, PhD		2,728
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets –  Dr. Larry Bernstein, Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN		2,715
VISION	Aviva Lev-Ari, PhD, RN	2,527
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community – Dr. Larry Bernstein, Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN		2,487
Funding, Deals & Partnerships – Aviva Lev-Ari, PhD, RN		2,436
Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I Dr. Larry Bernstein		2,318
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules –  Stephen J Williams, PhD		2,260
Bone regeneration and nanotechnology –  – Tilda Barliya, PhD		2,252
“The Molecular pathology of Breast Cancer Progression” –  – Tilda Barliya, PhD		2,233
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging – Dror Nir, PhD		2,150
About	Aviva Lev-Ari, PhD, RN	2,036
In focus: Circulating Tumor Cells – Ritu Saxena, PhD		2,034
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation – Dr. Larry Bernstein		2,016
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical) Larry H Bernstein, MD, FCAP and Justin D Pearlman, MD, PhD, FACC		1,983
Journal PharmaceuticalIntelligence.com – Aviva Lev-Ari, PhD, RN		1,977
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) – Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN		1,967
Problems of vegetarianism – Sudipta Saha, PhD		1,903
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment – Sudipta Saha, PhD		1,844
DNA Structure and Oligonucleotides – Larry H Bernstein, MD, FCAP		1,796
Targeting the Wnt Pathway [7.11] – Larry H Bernstein, MD, FCAP		1,759
Biosimilars: CMC Issues and Regulatory Requirements – Aviva Lev-Ari, PhD, RN		1,726
Interaction of enzymes and hormones – Sudipta Saha, PhD		1,716
Nitric Oxide and Platelet Aggregation – Dr. Venkat S. Karra, Ph.D.		1,713
CD47: Target Therapy for Cancer – Tilda Barliya, PhD		1,712
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes – Aviva Lev-Ari, PhD, RN		1,711
Introduction to Tissue Engineering; Nanotechnology applications Tilda Barliya, PhD		1,666
Non-small Cell Lung Cancer drugs – where does the Future lie? – Ritu Saxena, PhD		1,658
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node – Tilda Barliya, PhD		1,583
A Primer on DNA and DNA Replication – Larry H. Bernstein, MD, FCAP		1,572
Lipid Metabolism – Larry H. Bernstein, MD, FCAP		1,568
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB Aviva Lev-Ari, PhD, RN		1,532
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research – Stephen J Williams, PhD		1,489
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers – Aviva Lev-Ari, PhD, RN		1,459